Literature DB >> 19084348

Early clinical experience and outcome of helical tomotherapy for multiple metastatic lesions.

Ik Jae Lee1, Jinsil Seong, Chang Geol Lee, Yong Bae Kim, Ki Chang Keum, Chang Ok Suh, Gwi Eon Kim, Jaeho Cho.   

Abstract

PURPOSE: To evaluate the feasibility of synchronous treatment of multiple metastatic lesions by helical tomotherapy. METHODS AND MATERIALS: Forty-two patients with multiple metastatic lesions were treated by helical tomotherapy from April 2006 to February 2007. Among these patients, 21 had metastatic bone disease. Subjective pain response was assessed using the visual analogue scales, and morbidity was evaluated by Common Terminology Criteria for Adverse Events v3.0. The correlation between the percentage of red bone marrow in the radiation field and the severity of leukocytopenia was analyzed.
RESULTS: The median age was 57 years. Radiation dose to the gross tumor volume was 30-84 Gy, with a median fractional size of 3 Gy. Mean treatment time was 16 min and 1 sec. Treatment time and fraction size were modified because of poor performance status or hematologic toxicity in two patients. With regard to palliative effects for bone metastasis, 16 patients (76.2%) experienced positive pain relief. Four patients had Grade III leukocytopenia, and three had Grade IV leukocytopenia. In the multivariate logistic regression, red marrow percentage was the independent risk factor most associated with Grade III/IV leukocytopenia (p = 0.014). The tolerance cutoff point of red bone marrow was 26.8%, with a sensitivity and specificity of 85.7% and 85.7%, respectively.
CONCLUSIONS: Helical tomotherapy was effective for symptom palliation and was feasible for patients with multiple metastatic diseases. The volume of red bone marrow, as well as performance status, must be taken into account to determine optimal treatment.

Entities:  

Mesh:

Year:  2008        PMID: 19084348     DOI: 10.1016/j.ijrobp.2008.07.035

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Feasibility of intrafraction whole-body motion tracking for total marrow irradiation.

Authors:  Manju Sharma; Troy Dos Santos; Nikolaos P Papanikolopoulos; Susanta Kumar Hui
Journal:  J Biomed Opt       Date:  2011-05       Impact factor: 3.170

2.  Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer.

Authors:  Gowoon Yang; Jee Suk Chang; Jeong Eun Choi; Eun Sil Baek; Seung-Seob Kim; Hwa Kyung Byun; Yeona Cho; Woong Sub Koom; Seung Yoon Yang; Byung Soh Min; Sang Joon Shin
Journal:  Radiat Oncol       Date:  2022-05-21       Impact factor: 4.309

3.  Helical tomotherapy in the treatment of pediatric malignancies: a preliminary report of feasibility and acute toxicity.

Authors:  Latifa Mesbah; Raúl Matute; Sergey Usychkin; Immacolata Marrone; Fernando Puebla; Cristina Mínguez; Rafael García; Graciela García; César Beltrán; Hugo Marsiglia
Journal:  Radiat Oncol       Date:  2011-08-26       Impact factor: 3.481

4.  Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer.

Authors:  Sun Hyun Bae; Seong Kwon Moon; Yong Ho Kim; Kwang Hwan Cho; Eung Jin Shin; Moon Sung Lee; Chang Beom Ryu; Bong Min Ko; Jina Yun
Journal:  Radiat Oncol J       Date:  2015-12-30

5.  A planning study for palliative spine treatment using StatRT and megavoltage CT simulation.

Authors:  Yi Rong; Poonam Yadav; Bhudatt Paliwal; Lu Shang; James S Welsh
Journal:  J Appl Clin Med Phys       Date:  2010-10-30       Impact factor: 2.102

6.  Toxicity risk of non-target organs at risk receiving low-dose radiation: case report.

Authors:  Pei-Wei Shueng; Shih-Chiang Lin; Hou-Tai Chang; Ngot-Swan Chong; Yu-Jen Chen; Li-Ying Wang; Yen-Ping Hsieh; Chen-Hsi Hsieh
Journal:  Radiat Oncol       Date:  2009-12-31       Impact factor: 3.481

7.  Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?

Authors:  Yeona Cho; Jee Suk Chang; Koon Ho Rha; Sung Joon Hong; Young Deuk Choi; Won Sik Ham; Jun Won Kim; Jaeho Cho
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

8.  Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.

Authors:  Jun Won Kim; Jinsil Seong; Ik Jae Lee; Joong Yeol Woo; Kwang-Hyub Han
Journal:  Oncotarget       Date:  2016-06-28

9.  High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma.

Authors:  Taehyung Kim; Hye Jung Cha; Jun Won Kim; Jinsil Seong; Ik Jae Lee
Journal:  Oncotarget       Date:  2016-08-16

10.  Prospective evaluation of multitarget treatment of pediatric patients with helical intensity-modulated radiotherapy.

Authors:  Maria-Elena A Salfelder; Kerstin A Kessel; Uwe Thiel; Stefan Burdach; Severin Kampfer; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2020-08-03       Impact factor: 3.621

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.